GLOW: Three Repair Peptides, One Research Combination

The short version

GLOW is not a single molecule. It is a co-formulated research blend of three distinct peptides — most commonly GHK-Cu (the copper-carrying matrix-building tripeptide), BPC-157 (a pro-angiogenic synthetic pentadecapeptide), and TB-500 (a short fragment carrying the actin-binding motif of thymosin beta-4) — combined because their mechanisms are thought to be complementary: one builds the collagen-elastin scaffold, one grows the blood vessels that feed healing tissue, and one supports the cell migration that brings repair cells to the site.

The combination thesis makes mechanistic sense on paper. The clinical evidence behind it is much thinner. No controlled study has tested the GLOW blend itself — as a unit, at any specific ratio — in humans for any indication ^[8]. Every claim about the blend as a combination is an extrapolation from single-constituent research, much of it in animals ^[8][9]. This page covers what the underlying literature says, compound by compound, and is honest about where the extrapolation starts. No dose, no protocol, no medical advice.

What it is

GLOW is a supplier- and clinic-formulated co-mixture. Its three components are:

1. GHK-Cu — Glycyl-L-Histidyl-L-Lysine Copper(II) complex (approximately 402.9 Da). A copper-binding tripeptide drawn from the sequence of type I collagen; the matrix-remodeling and collagen-stimulating component.
2. BPC-157 — Body Protection Compound 157; a synthetic, stable pentadecapeptide (sequence GEPPPGKPADDAGLV, approximately 1,419 Da) derived from a gastric body-protection protein; the cytoprotective and pro-angiogenic component.
3. TB-500 — The acetylated heptapeptide Ac-LKKTETQ (approximately 889 Da), corresponding to the actin-binding region (residues 17-23) of thymosin beta-4; the cell-migration and anti-scarring component.

Ratios are formulation-specific and not standardized across suppliers. GLOW is distinct from KLOW and WOLVERINE — it does not contain the peptides specific to those other blends. None of these three peptides is approved for human use as a medicine; topical copper tripeptide-1 (GHK-Cu) is a legal cosmetic ingredient, while BPC-157 and TB-500 are unapproved research chemicals ^[8].

How it works

Each constituent contributes a different piece of the repair signal:

GHK-Cu (matrix arm). At picomolar-to-nanomolar concentrations it directly stimulates dermal fibroblast synthesis of collagen, elastin, glycosaminoglycans and the proteoglycan decorin, while rebalancing matrix metalloproteinases against their TIMP inhibitors. It also chemoattracts macrophages and other repair cells, suppresses TGF-beta-1 and TNF-alpha-driven inflammation, and stimulates synthesis of VEGF, FGF-2, NGF, and neurotrophins ^[4][6].

BPC-157 (vascular arm). Its best-characterized mechanism is pro-angiogenesis. In studies spanning chick chorioallantoic membrane, rat hind-limb ischemia, and human vascular endothelial cells, BPC-157 increased mRNA and protein expression of VEGFR2 (a key vessel-growth receptor), promoted VEGFR2 internalization, and time-dependently activated the VEGFR2-Akt-eNOS downstream pathway, increasing vessel density in the treated tissue ^[10]. In plain terms: it makes endothelial cells more responsive to the body's vessel-growth signal and accelerated blood-flow recovery in a blocked-circulation model ^[10].

TB-500 (cell-migration arm). The Ac-LKKTETQ sequence is the actin-binding motif of thymosin beta-4. By regulating G-actin (the free, mono-unit form of actin), this motif is associated with faster cell migration toward a wound, reduced scarring, and further angiogenic signaling. An important caveat applies here: most efficacy data for this mechanism use full-length thymosin beta-4 (which is about five times larger than the TB-500 fragment); whether the short fragment reproduces all of that in humans is not established ^[8].

The combination rationale. The thesis is complementary coverage: a matrix-building signal (GHK-Cu), a vascular/cytoprotective signal (BPC-157), and a cell-mobility/anti-scarring signal (TB-500) operating on different but convergent parts of tissue repair. No study has tested whether the three together outperform or interact differently than any one alone ^[8].

What the research shows

Because no study has tested GLOW as a blend, the relevant evidence is component-level — and it varies considerably by component.

For GHK-Cu (most human evidence). A 2015 review documents topical GHK-Cu increasing collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid, with placebo-controlled improvements in skin laxity, fine lines and wrinkle depth — all in topical application studies ^[4]. A 2008 foundational review catalogs the full angiogenic, anti-inflammatory, antioxidant, matrix-regulatory and neurotrophic profile ^[6]. The GHK-Cu arm is what gives the GLOW blend its skin-and-aesthetics identity.

For BPC-157 (mostly animal; three small human pilots). A 2025 narrative review examining BPC-157 for musculoskeletal healing found only three small human pilot studies in the literature — including an intraarticular knee pain study and an intravenous safety/pharmacokinetics pilot — with no adverse effects reported but no rigorous large-scale trials, concluding BPC-157 should be treated as investigational and used with caution ^[9]. The VEGFR2 mechanism study in endothelial cells and animal models provides the best mechanistic anchor for the vascular-repair contribution ^[10].

For the blend as a whole. A 2026 Sports Medicine narrative review specifically names BPC-157, TB-500 (thymosin beta-4 fragment), and GHK-Cu among unapproved peptide therapies for musculoskeletal conditions — and is explicit that many demonstrate favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce and there is potential for serious harm, with a gray market of such compounds operating largely outside regulatory oversight ^[8]. This is the single best blend-level anchor: a peer-reviewed review that names all three constituents together and is honest about the evidence and regulatory reality.

Reported effects, cautions & safety

What the research-use community reports (anecdotal, not clinical evidence): The signal the blend is named for — skin looking brighter and more radiant after a few weeks — is the most frequently reported benefit in clinic blog accounts and research-use-only write-ups about the GHK-Cu + BPC-157 + TB-500 stack, attributed mainly to the GHK-Cu arm. People also commonly describe smoother skin texture, improved hydration, and softer-looking fine lines, with longer-running accounts sometimes adding quicker-looking wound healing or scar appearance improvement attributed to the BPC-157 and TB-500 arms. Reduced hair shedding is occasionally mentioned, credited to the GHK-Cu component. Faster recovery from nagging tendon or joint discomfort — carried over from the BPC-157 and TB-500 individual-compound communities — is frequently mentioned alongside the skin effects.

On the downside: stinging or burning at the injection site is the most consistently mentioned complaint, typically brief (under a minute) and attributed to the GHK-Cu copper complex. Injection-site redness or itching lasting under a day is also commonly reported. Early-on fatigue, lethargy, or a mild headache in the first week or two is a recurring early-use report. Occasional warmth, flushing, or a metallic taste after injection is attributed to the copper arm. Mild bloating, transient nausea, or increased appetite are occasionally described. None of these accounts come from controlled clinical studies and none include a verified dose.

Cautions from the literature:

• Athletes: GLOW is off-limits for anti-doping purposes. The TB-500 component (thymosin beta-4 fragment) is named on the WADA Prohibited List (class S2, peptide hormones / growth factors and mimetics), banned at all times both in and out of competition. Because TB-500 is one of the three peptides in the blend, using GLOW implicates anti-doping rules regardless of the skin-focused framing. BPC-157 is separately prohibited under the WADA S0 non-approved substances category ^[8].
• The blend is untested as a combination. No combined safety or pharmacokinetic data exist for GHK-Cu + BPC-157 + TB-500 together. The three peptides clear at very different rates and have never been characterized as a co-formulation in controlled study ^[8].
• Pro-angiogenic peptides and cancer history. BPC-157 is pro-angiogenic via the VEGFR2 pathway, and TB-500/thymosin beta-4 similarly promotes angiogenesis and cell migration ^[10][8]. Because solid tumors depend on angiogenesis for their blood supply, accelerating new-vessel formation is a theoretical concern raised in the peptide literature. No human study has tested this risk for the GLOW blend; the caution is mechanistic, not a documented harm.
• Wilson's disease and copper-dysregulation conditions. The GHK-Cu arm is a copper(II)-tripeptide complex that delivers copper into tissue. People who cannot clear copper normally face a mechanistic concern about copper accumulation ^[5].
• Regulatory status. GLOW is not an FDA-approved drug product. BPC-157 was placed by the FDA in 2023 in a category of bulk drug substances not eligible for pharmacy compounding pending further evaluation. Injectable or systemic use of any component is research-only ^[8][9].
• BPC-157 is the weakest human-evidence component. The blend can be no better evidenced than its least-studied part; only three small human pilots exist for BPC-157, and they are safety or single-setting studies, not efficacy trials ^[9]. The combination inherits that investigational framing.

Where it fits in skin and aesthetics research

GLOW occupies a specific niche on this desk: a multi-peptide combination whose biological rationale is coherent but whose evidence as a blend is thin-to-nonexistent in humans. What it offers over GHK-Cu alone is a broader tissue-repair hypothesis — adding vascular and cell-migration coverage to the matrix-building signal. What it does not offer is clinical trial data for that combination, and the regulatory complications from the TB-500 and BPC-157 arms are concrete, not theoretical ^[8].

For readers whose main interest is in the skin firmness and elasticity angle, GHK-Cu is where the human topical evidence lives. GLOW is the broader-scope research combination. See how they compare on the comparison page.